The five main barriers for Orphan Drugs in Asia Pacific are (1) Market complexity (2) Regulatory strategy (3) Pharmaco-vigilance concerns (4) Ethical marketing and (5) Access to skilled regional management. This article focuses on the first ..
AFT Orphan Blog
China is changing its attitude to Orphan Drugs
Tuesday, January 03, 2012
China is changing its attitude to Orphan Drugs – what used to be a barren waste land could become the next major Orphan Drug opportunity.
..
1
Recent Posts
- Secure OD supply chains and PV reporting in Asia Pacific
- Following on............with Regulatory strategy for Orphan Drugs in Asia Pacific
- There are five main barriers (Regulatory covered this time) which reduce access for Orphan Drugs in Asia Pacific
- There are five main barriers for Orphan Drugs in Asia Pacific
- China is changing its attitude to Orphan Drugs
- Expanding patient access for Orphan Drugs in Asia Pacific
Tags
Archive
Tweet
